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CASE REPORT
INTRODUCTION
The prevalence1,2 and costs2 of dementia, of which Alzheimer’s 
dementia (AD)3 is the dominant subtype, are substantial.3 
AD is characterized by deficits in memory and executive 
function.4  Treatments have focused on pharmacotherapy,5 
but from 2002–2012 the US Food and Drug Administration 
has cleared only 1 of 244 drugs tested6 and no therapy halts 
disease progression.7  
The dual-drug hyperbaric oxygen therapy (HBOT)8,9 has 
many neurological applications.10  The first successful HBOT-
treated case of AD was published in 2001.11,12 The present 
case report is the first patient in a series of 11 HBOT-treated 
AD patients whose symptomatic improvement is documented 
with 18fluorodeoxyglucose positron emission tomography 
(18FDG PET). 
cASE HISTORY
The patient is a 58-year-old, Caucasian female with 5 years of 
cognitive decline that accelerated 8 months pre-HBOT. Seven 
months pre-HBOT extensive metabolic, vitamin deficiency, 
serologic, rheumatologic, imaging, cardiac, and medical 
evaluations, including apolipoprotein E (APOE) allele test-
ing (homozygous e3) were negative. Electroencephalogram 
showed diffuse slowing; neuropsychological testing demon-
strated multiple cognitive deficits. Single photon emission 
computed tomography (SPECT) was abnormal, suggesting 
AD (Figure 1). 18FDG PET imaging 6 months post-SPECT 
and 1 month pre-HBOT confirmed AD (Additional video 1). 
Medical history: natural gas inhalation-induced syncope at 
8–10 years old (subsequent referral for Special Education), 
decades’ exposure to metallurgy factory and oil refineries, 
chronic hypotension, and ten-year work exposure to mold 
pre-diagnosis. No substance abuse or family history of AD. 
Brother with dementia secondary to multiple concussions, 
substance abuse, electroconvulsive therapy. Physical exam: 
confusion following commands, slight tremor, decreased 
pinprick diffusely, bradykinesia, hyperreflexia, dysdiado-
chokinesia, finger-to-nose incoordination, and instability on 
deep knee bend, tandem gait, and Romberg. Patient refused 
medications except Lexapro and vitamins.
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Abstract
Figure 1: Single photon emission computed tomography brain blood flow 
imaging 7 months pre-hyperbaric oxygen therapy (selected transverse 
slices). Note significant regional reduction in flow to left posterior temporal-
parietal region (white arrows).  
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The patient received forty 1.15 atmosphere absolute/50 
minutes total treatment time, once per day, 5 days per week, 
HBOTs in 66 days. After 21 HBOTs the patient reported 
increased energy/activity level, mood, and ability to draw 
a correct clock face, perform activities of daily living, and 
work crossword puzzles. Rivastigmine patch was started and 
discontinued after one week due to ineffectiveness (patient 
report).  At completion of 40 HBOTs patient reported increased 
memory and concentration, sleep, conversation, appetite, abil-
ity to use the computer, more good days (5/7) than bad days, 
resolved anxiety, and decreased disorientation and frustration. 
Tremor, deep knee bend, tandem gain, and motor speed were 
improved. Repeat 18FDG PET imaging one month post HBOT 
showed global 6.5–38% improvement in brain metabolism 
(Additional Videos 2–6; Additional Tables 1–3).
Texture analysis demonstrated a global decrease in the co-
efficient of variation (CV) except in the Alzheimer’s typical 
ROIs (Additional Tables 4 and 5). Two months post-HBOT 
the patient felt a recurrence in her symptoms. She was retreated 
over the next 20 months with 56 HBOTs (total 96) at the same 
dose, supplemental oxygen, and medications with stability of 
her symptoms and Folstein Mini-Mental Status exam (Ad-
ditional Table 6). 
DISCUSSION
AD is a debilitating, costly, rapidly increasing neurological 
disorder for which there is no effective treatment.1-3 Etiol-
ogy is multifactorial, systemic, and immune health-related 
from insults that occur across the spectrum of life,13 result-
ing in reductions of brain regional metabolism.14 Causes 
include infection,13 diabetes mellitus,13 metabolic disorders,7 
and vascular factors.15,16 Four pathological processes have 
been identified17: vascular hypoperfusion of the brain (and 
disturbed microcirculation)18 with associated mitochondrial 
dysfunction,6 2) destructive protein inclusions (intracellular 
neurofibrillary tangles--phosphorylated and aggregated tau 
protein), and extracellular amyloid plaques,7 3) uncontrolled 
oxidative stress, and 4) proinflammatory immune processes13,19 
secondary to microglial and astrocytic dysfunction in the 
brain. While the vast majority of cases are sporadic, genetic 
predisposition20 and epigenetic changes have been implicated.21
Diagnosis is clinical and can be confirmed with 18FDG PET 
hypometabolism in established disease,22 but is less reliable 
in mild cognitive impairment.22-24 Primary treatment is with 
acetylcholinesterase inhibitors or the N-methyl-D-aspartate 
receptor antagonist memantine5 which have been shown to 
have positive impact on AD progression25 with no significant 
disease-modifying effects.26
HBOT is an epigenetic12 modulation of gene expression 
and suppression8,9 to treat wounds9 and disease pathophysiol-
ogy,27,28 particularly inflammation.29 HBOT targets all four 
of the pathological processes of AD by: 1)  affecting the 
microcirculation28,30-34 mitochondrial dysfunction35,36 and 
biogenesis,37,38 2) reducing amyloid burden and tau phos-
phorylation,39 3) controlling oxidative stress,40 and 4) reducing 
inflammation.29,39,41-43
AD was suggested by SPECT and confirmed after rapid 
clinical decline by 18FDG PET hypometabolism in the typi-
cal temporal-parietal and posterior cingulate areas.14,22,24 Forty 
HBOTs improved symptoms and resting global brain metabo-
lism (6.5–38%), including the watershed and posterior cingu-
late areas. The largest increases were seen in the anterior and 
mid-cingulate cortices and the least in the posterior cingulate 
and watershed areas.  To our investigation these results are the 
largest reported global and regional improvements in resting 
brain metabolism in AD. Test/retest in normal has shown 
0.48–9.85% increases in metabolism over 7–23 weeks,44 25 
weeks,45 and 17 days,46 while acetylcholinesterase inhibitors 
treatment has demonstrated regional increases,47,50 no change,48 
or decreases47-49 in resting metabolism. The largest increase 
in global metabolism (26.5%) was seen after 26 weeks of 
rivastigmine in responders during an activation task, but not 
in the temporal-parietal watershed or cingulate areas.51 
At the same time, texture results were mixed with a global 
decrease in CV52 except for the watershed areas which showed 
the opposite effect. This reduction in CV has corresponded to 
a visual pattern of smooth texture on SPECT seen in normal 
individuals and individuals with traumatic brain injury and 
post-traumatic stress disorder,52 carbon monoxide poison-
ing,53,54 decompression sickness,55 near-drowning,56 and cere-
bral palsy56 after both a single HBOT and course of HBOT. 
It suggests a non-specific global effect on different brain 
wounding/pathologies. The differential effect on CV and less 
robust metabolism increases in the watershed regions implies 
that the patient’s symptomatic improvement may be primar-
ily due to HBOT effects on the rest of the brain.  Regardless, 
HBOT in this patient may be the first drug to not only halt, but 
temporarily reverse disease progression in AD.  
In conclusion, a 9-week treatment of low-pressure HBOT 
(40 sessions) in a patient with AD caused a significant increase 
in global metabolism on 18FDG PET imaging with concomi-
tant symptomatic improvement. Mild symptomatic regression 
was treated with intermittent HBOT, normobaric oxygen, and 
medications to stabilize symptoms, suggesting the possibility 
of long-term HBOT treatment of AD with pharmacotherapy.
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Additional Table 1: 18Fluorodeoxyglucose positron emission tomography  transverse slice cortical ribbon 
and posterior temporal-parietal watershed regions of interest (caudal to cephalad) pre/post-hyperbaric 
oxygen therapy 
 Cortical Ribbon  Posterior Watersh Right Posterior Watersh Left 
Slice Pre Post % Δ Pre Post % Δ Pre  Post % Δ 
38/68 520 659 26.7 431 510 18.3 329 396 20.4 
39 515 653 26.8 391 465 18.9 352 435 23.6 
40 507 635 25.2 364 444 22.0 339 413 21.8 
41 506 629 24.3 355 447 25.9 344 409 18.9 
42 499 640 28.3 366 443 21.0 334 383 14.7 
43 512 642 25.4 383 438 14.4 317 363 14.5 
44 519 657 26.6 389 434 11.6 320 359 12.2 
45 528 642 21.6 398 446 12.1 316 338 6.96 
46 508 620 22.0 388 422 8.76 321 342 6.54 
Average 513 642 25.2 385 450 17.0 330 382 15.5 
Note:  Pre/post: pre/post-hyperbaric oxygen therapy. % Δ: (Post - Pre)/Pre × 100%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Additional Table 2: 
18
Fluorodeoxyglucose positron emission tomography coronal slice bilateral cingulate 
cortices regions of interest (anterior to posterior) pre/post-hyperbaric oxygen therapy 
Note:  Pre/post: pre/post-hyperbaric oxygen therapy. Change = Post - Pre. % Change = Change/Pre × 
100%. 
Slice number Pre Post  Change % Change 
40 475 609 134 28.2 
41 511 644 133 26.0 
42 468 624 156 33.3 
43 451 624 173 38.3 
44 478 658 180 37.7 
45 486 662 176 36.2 
46 516 659 143 27.7 
47 492 608 116 23.6 
48 517 602 85 16.4 
49 546 623 77 14.1 
Average   494 631 137 28.1 
Additional Table 3:
 18
Fluorodeoxyglucose positron emission tomography sagittal slice of bilateral 
cingulate cortex and ROI (right to left) pre/post hyperbaric oxygen therapy 
 
Note: ROI: Regions of interest; pre/post: pre/post-hyperbaric oxygen therapy. Change = Post - 
Pre. %Change = Change/Pre × 100%. 
 
Slice # Pre Post Change % Change 
60/128 430 553 123 28.6 
61 454 569 115 25.3 
62 495 606 111 22.4 
63 480 554 74 15.4 
64 491 548 57 11.6 
65 476 527 51 10.7 
Average 471 559 89 19.0 
Additional Table 4: Coefficient of variation in 
18
fluorodeoxyglucose positron emission tomography 
transverse slice of cortical ribbon and temporal-parietal watershed regions of interest (right to left) 
pre/post HBOT 
Slice # 
 Pre-HBOT    Post-HBOT  
Right post 
watershed 
Left post 
watershed 
Cortical 
ribbon 
 Right post 
watershed 
Left post 
watershed 
Cortical 
ribbon 
38/68 20.1 40.4 26.7  21.4 41.9 20.3 
39 21.7 28.7 26.8  23.4 31.3 20.4 
40 23.3 32.2 27.8  26.8 32.2 22.0 
41 21.1 26.6 26.9  20.1 26.2 21.9 
42 20.5 28.1 27.7  25.5 29.8 21.7 
43 18.8 27.4 24.2  26.0 33.3 23.8 
44 22.4 25.6 22.9  27.6 33.4 22.8 
45 22.4 29.1 21.8  25.3 39.0 22.7 
46 28.1 29.9 27.4  34.4 38.6 26.5 
Average/change 22.0 29.8 25.8  25.6/+3.6 34.0/+4.2 22.5/-3.3 
Note: HBOT: Hyperbaric oxygen therapy. 
 
Additional Table 5: Coefficient of variation in 
18
fluorodeoxyglucose positron emission tomography coronal 
slice of cingulate cortices (anterior to posterior) pre/post HBOT 
Slice # Pre-HBOT Post-HBOT Change 
40/81 26.5 21.0 -5.5 
41 20.3 16.9 -3.4 
42 22.4 18.4 -4.0 
43 27.1 20.5 -6.6 
44 22.8 14.7 -8.1 
45 25.7 15.9 -9.8 
46 21.0 16.6 -4.4 
47 22.4 19.9 -2.5 
48 20.5 20.6 +0.1 
49 20.9 20.2 -0.7 
Average 23.0 18.5 -4.5 
 
Note:  HBOT: Hyperbaric oxygen therapy. Change = Post-HBOT - Pre-HBOT. 
 
 
Additional Table 6: Post-40 HBOTs (after August 2016) clinic course with Folstein Mini-Mental Status 
Scores 
Months 
post 40th 
HBOT 
Number 
of HBOTs 
Folstein 
Mini Mental 
Status 
Notes 
5 40 22 Begins oxygen concentrator two weeks before this 
date at  2 L/min x 20 minutes (2-5 sessions), 3 
times/week and restarts Rivastigmine patch for 4 
weeks, 4 weeks post this date  
9 70 23  
12 70 23 Restart Rivastigmine 
18 88 19 Discontinue Rivastigmine, start Donepezil, 5 mg/d 
22 96 22  
Note: HBOT: Hyperbaric oxygen therapy. 
 
 
